Company Overview and News

 
Eyenovia Appoints Three Industry Veterans to Board of Directors

2018-03-26 globenewswire
NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced that it has appointed directors Kenneth B. Lee, Jr., Charles E. Mather IV and Anthony Y. Sun, as independent members of its Board of Directors, effective immediately.
Upvote Downvote

2
Aralez Pharmaceuticals: Oversold And Undervalued

2018-03-15 seekingalpha
Q4 net revenues of $28 million and 2017 full year net revenues of $105.9 million exceeded guidance.
Upvote Downvote

 
BRIEF-Aralez Pharmaceuticals Inc - ‍On March 13, Board Appointed Michael Kaseta As Company's CFO - SEC Filing

2018-03-14 reuters
* ARALEZ PHARMACEUTICALS INC - ON MARCH 13, BOARD APPOINTED MICHAEL KASETA AS COMPANY'S CFO - SEC FILING Source text (bit.ly/2p8Z0x1) Further company coverage: (Reuters.Brief@thomsonreuters.com)
Upvote Downvote

 
ARLZ / Aralez Pharmaceuticals Inc. 10-K (Annual Report)

2018-03-14 sec.gov
arlz_Current_Folio_10K Table of Contents
Upvote Downvote

1
Aralez Pharmaceuticals' (ARLZ) CEO Adrian Adams on Q4 2017 Results - Earnings Call Transcript

2018-03-13 seekingalpha
Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Q4 2017 Results Earnings Conference Call March 13, 2018 8:30 AM ET
Upvote Downvote

 
Aralez Pharmaceuticals Inc. 2017 Q4 - Results - Earnings Call Slides

2018-03-13 seekingalpha
The following slide deck was published by Aralez Pharmaceuticals Inc. in conjunction with their 2017 Q4 earnings call.
Upvote Downvote

 
ARLZ / Aralez Pharmaceuticals Inc. / PAR INVESTMENT PARTNERS LP - SC 13G/A (Passive Investment)

2018-02-16 sec.gov
SC 13G/A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)*     Aralez Pharmaceuticals Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 03852X100 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☒Rule 13d-1(c) ☐ Rule 13d-1(d)  
Upvote Downvote

 
ARLZ / Aralez Pharmaceuticals Inc. / PAR INVESTMENT PARTNERS LP - SC 13G/A (Passive Investment)

2018-02-15 sec.gov
SC 13G/A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)*     Aralez Pharmaceuticals Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 03852X100 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☒Rule 13d-1(c) ☐ Rule 13d-1(d)  
Upvote Downvote

1
ARLZ / Aralez Pharmaceuticals Inc. / Flynn James E - 3G/A (Passive Investment)

2018-02-14 sec.gov
  SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   SCHEDULE 13G  (Rule 13d-102)   INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)   (Amendment No. 2) *   Aralez Pharmaceuticals, Inc. (Name of Issuer)   Common Shares (Title of Class of Securities)   03852X100 (CUSIP Number)   December 31, 2017  (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the ru
Upvote Downvote

 
ARLZ / Aralez Pharmaceuticals Inc. / Flynn James E - 3G/A (Passive Investment)

2018-02-14 sec.gov
  SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   SCHEDULE 13G  (Rule 13d-102)   INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)   (Amendment No. 2) *   Aralez Pharmaceuticals, Inc. (Name of Issuer)   Common Shares (Title of Class of Securities)   03852X100 (CUSIP Number)   December 31, 2017  (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the ru
Upvote Downvote

ARLZ : Aralez Pharmaceuticals Stock Analysis and Research Report

2017-10-23 - Asif

Aralez is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients’ lives while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Its parent corporation, Aralez Pharmaceuticals Inc., was incorporated under the British Columbia Business Corporations Act (“BCBCA”) on December 2, 2015. its global headquarters is located in Mississauga, Ontario, Canada, its U.S. headquarters is located in Princeton, New Jersey, United States, and its Irish headquarters is located in Dublin, Ireland. Aralez was formed for the purpose of facilitating the business combination of POZEN Inc., a Delaware corporation (“Pozen”), and Tribute Pharmaceuticals Canada Inc., a corporation incorporated under the laws of the Province of Ontario, Canada (“Tribute”), which transaction closed on February 5, 2016. On February 5, 2016, pursuant to an Agreement and Plan of Merger and Arr...

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

11h - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

CUSIP: 03852X100